Pediatrix Medical Group, Inc. (NYSE:MD) Given Consensus Rating of “Hold” by Analysts

Shares of Pediatrix Medical Group, Inc. (NYSE:MD) have been assigned a consensus rating of “Hold” from the five research firms that are currently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold rating. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $9.30.

Several equities research analysts have recently commented on the stock. StockNews.com upgraded shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research note on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft upgraded shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating and set a $8.00 target price on the stock in a research note on Friday, June 7th. Truist Financial boosted their target price on shares of Pediatrix Medical Group from $8.00 to $10.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Finally, UBS Group upped their price target on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a research report on Friday, August 9th.

Insiders Place Their Bets

In other news, Director Laura A. Linynsky sold 7,000 shares of the company’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the completion of the sale, the director now directly owns 30,805 shares of the company’s stock, valued at approximately $343,783.80. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CEO James D. Swift sold 11,100 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $10.79, for a total transaction of $119,769.00. Following the completion of the sale, the chief executive officer now directly owns 170,001 shares of the company’s stock, valued at approximately $1,834,310.79. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Laura A. Linynsky sold 7,000 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now directly owns 30,805 shares of the company’s stock, valued at $343,783.80. The disclosure for this sale can be found here. In the last three months, insiders sold 68,100 shares of company stock valued at $701,889. 2.00% of the stock is currently owned by insiders.

Institutional Trading of Pediatrix Medical Group

A number of large investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. boosted its position in Pediatrix Medical Group by 10.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,634,065 shares of the company’s stock worth $15,197,000 after acquiring an additional 148,600 shares during the last quarter. Jump Financial LLC acquired a new stake in shares of Pediatrix Medical Group in the 4th quarter valued at approximately $154,000. Dimensional Fund Advisors LP boosted its holdings in shares of Pediatrix Medical Group by 1.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 4,409,884 shares of the company’s stock valued at $41,013,000 after buying an additional 59,336 shares during the last quarter. Dynamic Technology Lab Private Ltd boosted its holdings in shares of Pediatrix Medical Group by 268.3% in the 4th quarter. Dynamic Technology Lab Private Ltd now owns 41,364 shares of the company’s stock valued at $385,000 after buying an additional 30,134 shares during the last quarter. Finally, Trexquant Investment LP lifted its holdings in Pediatrix Medical Group by 51.3% during the 4th quarter. Trexquant Investment LP now owns 128,353 shares of the company’s stock valued at $1,194,000 after purchasing an additional 43,545 shares during the last quarter. 97.71% of the stock is owned by institutional investors.

Pediatrix Medical Group Trading Down 2.9 %

Shares of Pediatrix Medical Group stock opened at $10.56 on Friday. The firm has a market capitalization of $888.59 million, a PE ratio of -12.42, a price-to-earnings-growth ratio of 1.68 and a beta of 1.56. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.38 and a quick ratio of 1.38. The company’s fifty day moving average price is $9.71 and its two-hundred day moving average price is $8.82. Pediatrix Medical Group has a 52-week low of $6.62 and a 52-week high of $13.01.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.03. The firm had revenue of $504.30 million for the quarter, compared to analyst estimates of $505.49 million. Pediatrix Medical Group had a negative net margin of 12.58% and a positive return on equity of 10.59%. The business’s revenue for the quarter was up .7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.37 EPS. On average, analysts expect that Pediatrix Medical Group will post 1.18 EPS for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.